CD8A and neoplasm: One of the most important features of the combination therapy was its ability to enhance both CD4+ and CD8+ T-cell responses against the tumor antigen Twist in the lung (Figures 4C and 6D), which likely resulted from increased T-cell priming at the vaccine DLN (Figures 4B and 6B).